Vyteris, Inc. (OTC BB: VYTR), the maker of the first active drug delivery patch to receive market approval from the (FDA), was founded with the purpose of developing, manufacturing and commercializing pharmaceutical products based upon novel, advanced drug delivery technology. This technology delivers drugs through the skin using low-level electrical energy, causing little to no disturbance. By utilizing Vyteris’ technology, many of the shortcomings of existing drug delivery methods can be eliminated or minimized. For further information, visit the Company’s web site at www.vyteris.com.
- 17 years ago
QualityStocks
Vyteris, Inc. (OTC BB: VYTR)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Secures Up to $100 Million in Project Financing for 97 MW U.S. Solar Portfolio
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has…
-
QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Bollinger Delivers EV Truck to LES Ecology Center
Mullen Automotive (NASDAQ: MULN) announced that its subsidiary, Bollinger Motors, has delivered a Bollinger B4…
-
QualityStocksNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) CEO to Present Live via Skyline Signature Series on May 7
FingerMotion (NASDAQ: FNGR), a mobile services, data and technology company, announced that CEO Martin J.…